Ask AI

Beyond A1C in Modern T2D Care: A Practical Primary Care Plan for CKM Risk Integration

Clinical Thought
Clinical Thought Start Activity
This activity is available for 0.50 CME/CE credit(s).

Released: August 20, 2026

Expiration: August 19, 2027

See Activity Collection

Modern type 2 diabetes (T2D) management must move beyond glycemic control alone by integrating cardiovascular-kidney-metabolic risk assessment and streamlined treatment planning into routine clinical decision-making in the primary care setting. Learn how incretin-based therapies can address patients’ T2D and greater CKM risk profile, then take home strategies for integrating these novel, organ-protective therapies into your practice through shared decision-making and personalized care plans.

CKM risk in T2D care

Pre Assessment

Assess your current knowledge and clinical approach before beginning your ClinicalThought.
1.

How many people with diabetes do you provide care for in a typical week?​

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A 58-year-old patient with T2D started a weekly GLP-1–based therapy 3 weeks ago. They report nausea, early satiety, and constipation. They have not had severe abdominal pain, vomiting, dehydration, or gallbladder symptoms. They are considering stopping therapy.

Which strategy best supports long-term persistence and adherence?